FDA 483 - BioLife Plasma Services LP - December 05, 2025

An FDA inspection of BioLife Plasma Services LP in Fort Worth, TX, revealed three significant observations. The firm failed to ensure donor privacy during screening, inadequately investigated a missing plasma unit, and maintained unsanitary conditions with widespread litter in manufacturing and screening areas. These issues indicate a lack of adherence to proper operational and quality standards.